Advances in Immunotherapy for Melanoma: A Comprehensive Review

Mediators of Inflammation

Volumn 2017, Issue , 2017, Pages

  Rodríguez Cerdeira, Carmen ^a   Gregorio, Miguel Carnero ^a   López Barcenas, Adriana ^b   Sánchez Blanco, Elena ^c   Sánchez Blanco, Beatriz ^d   Fabbrocini, Gabriella ^e   Bardhi, Brunilda ^f   Sinani, Ardiana ^g   Guzman, Roberto Arenas ^b  

^a UNIVERSITY OF VIGO   (Spain)

^b HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

^c Health Department   (Spain)

^d Galician Health Service   (Spain)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f Venus Clinic   (Albania)

^g Department of Orthopaedics Trauma Hospital Centre   (Albania)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DENDRITIC CELL VACCINE; DNA VACCINE; NEOANTIGEN; PEPTIDE VACCINE; UNCLASSIFIED DRUG; VACCINE; VECTOR BASED VACCINE; CANCER VACCINE;

BIOLOGICAL THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; HUMAN; IMMUNE RESPONSE; MELANOMA; NONHUMAN; PREDICTIVE VALUE; REVIEW; THERAPY EFFECT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; CYTOLOGY; DENDRITIC CELL; IMMUNOTHERAPY; METABOLISM; PROCEDURES; T LYMPHOCYTE;

CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MELANOMA; T-LYMPHOCYTES;

EID: 85034593273     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2017/3264217     Document Type: Review

References (46)

1. E. J. Lipson, W. H. Sharfman, S. Chen et al., "Safety and immunologic correlates of melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting," Journal of Translational Medicine, vol. 13, p. 214, 2015.
2. K. L. Kaufman, S. Mactier, N. J. Armstrong et al., "Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients," Clinical &Experimental Metastasis, vol. 31, no. 4, pp. 407-421, 2014.
3. S. P. Leong, M. C. Mihm Jr., G. F. Murphy et al., "Progression of cutaneous melanoma: implications for treatment," Clinical &Experimental Metastasis, vol. 29, no. 7, pp. 775-796, 2012.
4. M. Kanehisa, M. Furumichi, M. Tanabe, Y. Sato, and K. Morishima, "KEGG: new perspectives on genomes, pathways, diseases and drugs," Nucleic Acids Research, vol. 45, no. D1, pp. D353-D361, 2017.
5. A. Ascierto, M. Atkins, and C. Bifulco, "Future perspectives in melanoma research: meeting report from the "melanoma bridge": Napoli, December 3rd-6th 2014," Journal of Translational Medicine, vol. 30, no. 13, p. 374, 2015.
6. S. Rajkumarand and I. R. Watson, "Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies," British Journal of Cancer, vol. 115, no. 2, pp. 145-155, 2016.
7. D. B. Johnson and I. Puzanov, "Treatment of NRAS-mutant melanoma," Current Treatment Options in Oncology, vol. 16, no. 4, p. 15, 2015.
8. D. B. Johnson and S. Keiran M. Smalley, A. Jeffrey, and A. Sosman, "Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia," Clinical Cancer Research, vol. 20, no. 16, pp. 4186-4192, 2014.
9. S. Mocelli, S. Pasquali, C. D. Rossi, and D. Nitti, "Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis," Journal of the National Cancer Institute, vol. 102, no. 7, pp. 493-501, 2010.
10. V. G. Y. Nanda, W. Peng, P. Hwu et al., "Melanoma and immunotherapy bridge 2015," Journal of Translational Medicine, vol. 14, Supplement 1, p. 65, 2016.
11. S. J. Santegoets, M. J. Welters, and S. H. v. d. Burg, "Monitoring of the immune dysfunction in cancer patients," Vaccines (Basel), vol. 4, no. 3, p. E29, 2016.
12. S. Farkona, E. P. Diamandis, and I. M. Blasutig, "Cancer immunotherapy: the beginning of the end of cancer?," BMC Medicine, vol. 5, no. 14, p. 73, 2016.
13. X. Li, W. Hu, X. Zheng et al., "Emerging immune checkpoints for cancer therapy," Acta Oncologica, vol. 54, no. 10, pp. 1706-1713, 2015.
14. S. N. Linch, M. J. McNamara, and W. L. Redmond, "OX40 agonists and combination immunotherapy: putting the pedal to the metal," Frontiers in Oncology, vol. 5, p. 34, 2015.
15. A. Contreras, S. Sen, A. J. Tatar et al., "Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice," Cancer Immunology and Immunotherapy, vol. 65, no. 5, pp. 601-611, 2016.
16. A. Redeker and R. Arens, "Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination," Frontiers in Immunology, vol. 7, p. 345, 2016.
17. S. H. Albeituni, C. Ding, and J. Yang, "Hampering immune suppressors: therapeutic targeting of myeloidderived suppressor cells in cancer," Cancer Journal, vol. 19, no. 6, pp. 490-501, 2013.
18. S. Chen, R. Ding, and Y. Zhou, "Immunomodulatory effects of polysaccharide from marine fungus Phoma herbarum YS4108on T cells and dendritic cells," Mediators of Inflammation, vol. 2014, Article ID 738631, 13 pages, 2014.
19. M. Dany, R. Nganga, A. Chidiac, E. Hanna, S. Matar, and D. Elston, "Advances in immunotherapy for melanoma management," Human Vaccines &Immunotherapeutics, vol. 25, pp. 1-11, 2016.
20. N. Vigneron, "Human tumor antigens and cancer immunotherapy," Biomedical Research International, vol. 2015, Article ID 948501, 17 pages, 2015.
21. C. Giampietri, S. Petrungaro, S. Conti, A. Facchiano, A. Filippini, and E. Ziparo, "Cancer microenvironment and endoplasmic reticulum stress response," Mediators of Inflammation, vol. 2015, Article ID 417281, 11 pages, 2015.
22. R. Engelstein, S. Merims, G. Eisenberg et al., "Immune monitoring of patients treated with a whole-cell melanoma vaccine engineered to express 4-1BBL," Journal of Immunotherapy, vol. 39, no. 8, pp. 321-328, 2016.
23. Q. Zeng, H. Li, H. Jiang et al., "Tailoring polymeric hybrid micelles with lymph node targeting ability to improve the potency of cancer vaccines," Biomaterials, vol. 122, pp. 105-113, 2017.
24. K. K. Ahmed, S. M. Geary, and A. K. Salem, "Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines," Journal of Controlled Release, vol. 248, pp. 1-9, 2017.
25. F. C. Stark, M. J. McCluskie, and L. Krishnan, "Homologous prime-boost vaccination with OVA entrapped in self-adjuvant in garchaeosomes induces high numbers of OVA-specific CD8+ T cells that protect against subcutaneous B16-OVA melanoma," Vaccines (Basel), vol. 4, no. 4, p. 44, 2016.
26. X. Dai, Y. He, W. Yao, and X. Gao, "Establishment of a spontaneous metastasis tumor model for human ErbB-2 vaccine," Biomedicine &Pharmacotherapy, vol. 88, pp. 991-998, 2017.
27. V. Verma, Y. Kim, M. C. Lee et al., "Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression," Oncotarget, vol. 7, no. 26, pp. 39894-39906, 2016.
28. L. Bronchalo-Vicente, E. Rodriguez-Del Rio, J. Freire et al., "A novel therapy for melanoma developed in mice: transformation of melanoma into dendritic cells with Listeria monocytogenes," PLoS One, vol. 10, no. 3, article e0117923, 2015.
29. BioCarta, "Charting Pathways of Life," http://www.biocarta. com/.
30. R. Calderon-Gonzalez, L. Bronchalo-Vicente, J. Freire et al., "Exceptional antineoplastic activity of a dendritic-celltargeted vaccine loaded with a Listeria peptide proposed against metastatic melanoma," Oncotarget, vol. 7, no. 13, pp. 16855-16865, 2016.
31. T. Z. Iversen, "Immune modulations during chemoimmunotherapy and novel vaccine strategies in metastatic melanoma and non small-cell lung cancer," The Danish Medical Journal, vol. 60, no. 12, article B4774, 2013.
32. Y. Hu, H. Kim, C. M. Blackwell, and C. L. Slingluff Jr., "Long-term outcomes of helper peptide vaccination for metastatic melanoma," Annals of Surgery, vol. 262, no. 3, pp. 456-464, 2015.
33. C. M. Reed, N. D. Cresce, I. S. Mauldin, C. L. Slingluff Jr., and W. C. Olson, "Vaccination with melanoma helper peptides induces antibody responses associated with improved overall survival," Clinical Cancer Research, vol. 21, no. 17, pp. 3879-3887, 2015.
34. R. Gutzmer, L. Rivoltini, E. Levchenko et al., "Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study," ESMO Open, vol. 1, no. 4, article e000068, 2016.
35. T. Kumai, S. Lee, H. I. Cho et al., "Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses," Cancer Immunology Research, vol. 5, no. 1, pp. 72-83, 2016.
36. M. Hirvinen, C. Capasso, K. Guse et al., "Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity," Molecular Therapy Oncolytics, vol. 23, no. 3, article 16002, 2016.
37. P. H. Lizotte, A. M. Wen, M. R. Sheen et al., "In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer," Nature Nanotechnology, vol. 11, no. 3, pp. 295-303, 2016.
38. S. Y. Kim, D. Kang, H. J. Choi, Y. Joo, J. H. Kim, and J. J. Song, "Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation," Oncotarget, 2017.
39. J. T. Gordy, K. Luo, H. Zhang, A. Biragyn, and R. B. Markham, "Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model," Journal for Immunotherapy of Cancer, vol. 4, p. 96, 2016.
40. S. X. Zhang, "Turning killer into cure\-The story of oncolytic herpes simplex viruses," Discovery Medicine, vol. 20, no. 111, pp. 303-309, 2015.
41. M. Huo, Y. Zhao, A. B. Satterlee, Y. Wang, Y. Xu, and L. Huang, "Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment," Journal of Controlled Release, vol. 245, pp. 81-94, 2016.
42. R. P. Sahu, M. Ferracini, and J. B. Travers, "Systemic chemotherapy is modulated by platelet-activating factor-receptor agonists," Mediators of Inflammation, vol. 2015, Article ID 820543, 6 pages, 2015.
43. C. Cui, B. Tang, and J. Guo, "Chemotherapy, biochemotherapy and anti-VEGF therapy in metastatic mucosal melanoma," Chinese Clinical Oncology, vol. 3, no. 3, p. 36, 2016.
44. S. Theurich, S. I. Rothschild, and M. Hoffmann, "Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma," Cancer Immunology Research, vol. 4, no. 9, pp. 744-754, 2016.
45. M. V. Heppt, T. K. Eigentler, K. C. Kähler et al., "Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis," Cancer Immunology &Immunotherapy, vol. 65, no. 8, pp. 951-959, 2016.
46. O. Franzese, B. Palermo, C. D. Donna et al., "Poly functional Melan-A-specific tumor-reactive CD8+ T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS," Oncoimmunology, vol. 5, no. 55, article e1114203, 2016.